Lin X, Gupta D, Vaitsiankova A, Bhandari S, Leung K, Menolfi D
Mol Cell. 2024; 84(20):3916-3931.e7.
PMID: 39383878
PMC: 11615737.
DOI: 10.1016/j.molcel.2024.09.020.
Szanto M, Yelamos J, Bai P
Expert Rev Mol Med. 2024; 26:e13.
PMID: 38698556
PMC: 11140550.
DOI: 10.1017/erm.2024.14.
Frimpong E, Bulusu R, Okoro J, Inkoom A, Ndemazie N, Rogers S
Eur J Pharm Sci. 2024; 196():106754.
PMID: 38554983
PMC: 11229414.
DOI: 10.1016/j.ejps.2024.106754.
Bailey M, Morand S, Royfman R, Lin L, Singh A, Stanbery L
Int J Mol Sci. 2024; 25(6).
PMID: 38542143
PMC: 10970335.
DOI: 10.3390/ijms25063173.
Marques Freire Cunha S, Lam S, Mallard B, Karrow N, Canovas A
Genes (Basel). 2024; 15(2).
PMID: 38397178
PMC: 10888242.
DOI: 10.3390/genes15020187.
Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization.
Zhang Y, Liang L, Li Z, Huang Y, Jiang M, Zou B
Front Oncol. 2023; 13:1295579.
PMID: 38111536
PMC: 10726039.
DOI: 10.3389/fonc.2023.1295579.
PARP1 Characterization as a Potential Biomarker for p190+ Acute Lymphoblastic Leukemia.
Machado C, da Silva E, Ferreira W, DE Pinho Pessoa F, de Quadros A, Fantacini D
Cancers (Basel). 2023; 15(23).
PMID: 38067214
PMC: 10705790.
DOI: 10.3390/cancers15235510.
Frequency of peripheral PD-1regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer.
Park J, Kim J, Lee M, Lee J, Kim Y, Lee Y
Br J Cancer. 2023; 129(11):1841-1851.
PMID: 37821637
PMC: 10667217.
DOI: 10.1038/s41416-023-02455-z.
PARP2 downregulation in T cells ameliorates lipopolysaccharide-induced inflammation of the large intestine.
Bencsics M, Banyai B, Ke H, Csepanyi-Komi R, Sasvari P, Dantzer F
Front Immunol. 2023; 14:1135410.
PMID: 37457706
PMC: 10347374.
DOI: 10.3389/fimmu.2023.1135410.
PARP2 poly(ADP-ribosyl)ates nuclear factor erythroid 2-related factor 2 (NRF2) affecting NRF2 subcellular localization.
Janko L, Toth E, Laczik M, Rauch B, Janka E, Balint B
Sci Rep. 2023; 13(1):7869.
PMID: 37188809
PMC: 10185692.
DOI: 10.1038/s41598-023-35076-w.
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.
Concannon K, Morris B, Gay C, Byers L
Mol Cell. 2023; 83(5):660-680.
PMID: 36669489
PMC: 9992136.
DOI: 10.1016/j.molcel.2022.12.031.
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
Li S, Wang L, Wang Y, Zhang C, Hong Z, Han Z
J Hematol Oncol. 2022; 15(1):147.
PMID: 36253861
PMC: 9578258.
DOI: 10.1186/s13045-022-01360-x.
Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.
Xie T, Dickson K, Yee C, Ma Y, Ford C, Bowden N
Cancers (Basel). 2022; 14(19).
PMID: 36230543
PMC: 9563432.
DOI: 10.3390/cancers14194621.
Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.
Bound N, Vandenberg C, Kartikasari A, Plebanski M, Scott C
Front Genet. 2022; 13:886170.
PMID: 36159999
PMC: 9505691.
DOI: 10.3389/fgene.2022.886170.
Comprehensive analyses identify RIPOR2 as a genomic instability-associated immune prognostic biomarker in cervical cancer.
Xu F, Zou C, Gao Y, Shen J, Liu T, He Q
Front Immunol. 2022; 13:930488.
PMID: 36091054
PMC: 9458976.
DOI: 10.3389/fimmu.2022.930488.
Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment.
Xu Q, Liu X, Mohseni G, Hao X, Ren Y, Xu Y
Cancer Cell Int. 2022; 22(1):242.
PMID: 35906622
PMC: 9338646.
DOI: 10.1186/s12935-022-02664-1.
The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
Maiorano B, Lorusso D, Maiorano M, Ciardiello D, Parrella P, Petracca A
Int J Mol Sci. 2022; 23(7).
PMID: 35409229
PMC: 8998760.
DOI: 10.3390/ijms23073871.
PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites.
Lin X, Jiang W, Rudolph J, Lee B, Luger K, Zha S
Nucleic Acids Res. 2022; 50(7):3958-3973.
PMID: 35349716
PMC: 9023293.
DOI: 10.1093/nar/gkac188.
Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
Wang M, Chen S, Ao D
MedComm (2020). 2022; 2(4):654-691.
PMID: 34977872
PMC: 8706759.
DOI: 10.1002/mco2.103.
Impact of DNA Damage Response-Targeted Therapies on the Immune Response to Tumours.
Lutfi N, Galindo-Campos M, Yelamos J
Cancers (Basel). 2021; 13(23).
PMID: 34885119
PMC: 8656491.
DOI: 10.3390/cancers13236008.